Andrew Reardon sold $1.5M of LGND
CLO & Secretary at LIGAND PHARMACEUTICALS INC. 5,000 shares at an average of $304.07, traded Oct 2, 2026, filed Oct 6, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.5M at market
- +5Share of holdings soldSold 14% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001950232-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | MOption exercise Common Stock10b5-1 | +340 | $52.27 | $18k | 36,854 | 6 d ago |
| Oct 2, 2026 | SOpen-market sale Common Stock10b5-1 | -833 | $302.51 | $252k | 36,021 | 6 d ago |
| Oct 2, 2026 | SOpen-market sale Common Stock10b5-1 | -1,976 | $303.54 | $600k | 34,045 | 6 d ago |
| Oct 2, 2026 | SOpen-market sale Common Stock10b5-1 | -1,535 | $304.52 | $467k | 32,510 | 6 d ago |
| Oct 2, 2026 | SOpen-market sale Common Stock10b5-1 | -404 | $306.18 | $124k | 32,106 | 6 d ago |
| Oct 2, 2026 | SOpen-market sale Common Stock10b5-1 | -235 | $307.19 | $72k | 31,871 | 6 d ago |
| Oct 2, 2026 | SOpen-market sale Common Stock10b5-1 | -17 | $307.74 | $5,232 | 31,854 | 6 d ago |
| Oct 2, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -340 | $0.00 | $0 | 29,104 | 6 d ago |
Related signals
Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | LIGAND PHARMACEUTICALS INC | Martine Zimmermann director | $342k 1,200 shares | -24% | |
| 33Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -12% | |
| 45Moderate | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $340k 1,804 shares | -6% | |
| 12Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $91k 467 shares | -1% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | Nancy Ryan Gray director | $1.4M 6,571 shares | -56% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | John L Lamattina director | $859k 4,179 shares | -13% | |
| 19Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $89k 467 shares | -1% | |
| 12Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $84k 467 shares | -1% | |
| 53Moderate | LIGAND PHARMACEUTICALS INC | Jason Aryeh director | $1.7M 10,000 shares | -13% | |
| 3Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $76k 467 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.